文献速递白血病

初诊急性髓系白血病合并骨髓纤维化的临床特征、基因突变及预后分析

[Analysis of clinical features, gene mutation, and prognostic characteristics in de novo acute myeloid leukemia patients with myelofibrosis].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2020-01-01

该回顾性研究纳入103例初诊AML并行骨髓活检患者,比较伴与不伴骨髓纤维化(MF)两组的临床特征、基因突变及预后。结果显示MF是影响完全缓解、总生存和无进展生存的独立危险因素,MF评估对初诊AML疗效和预后判断具有重要意义。

要点

  • AML伴MF组完全缓解率显著低于不伴MF组(69.7%对93.2%,P=0.006)。
  • MF是初诊AML患者完全缓解的独立危险因素。
  • MF尤其是MF-2/3是OS和PFS的独立危险因素,评估MF有预后价值。

核心结论

  • MF是影响初诊AML患者CR、OS和PFS的独立预后不良指标。
  • MF评估对初诊AML的疗效和预后判断具有重要意义。

研究设计与样本

  • 回顾性研究纳入2016年1月1日至2020年2月1日河南省人民医院103例初诊AML且同时行骨髓活检的患者。
  • 按WHO(2016)骨髓纤维化分级分为AML伴MF组(MF-1~3,46例)与AML不伴MF组(MF-0,57例)。

主要发现

  • AML伴MF组中位WBC显著高于不伴MF组[11.205(0.69~191.82)×10^9/L对4.64(0.18~95.10)×10^9/L,P=0.024]。
  • AML伴MF组外周血有核红细胞比例明显增高(43.5%对24.6%,χ²=4.119,P=0.042)。
  • AML伴MF组FLT3-ITD及NPM1突变率更高(15.2%对1.8%,P=0.021;26.1%对10.5%,P=0.039),CEBPA突变率更低(2.2%对17.5%,P=0.029)。
  • AML伴MF组CR率显著低于不伴MF组(69.7%对93.2%,χ²=7.412,P=0.006)。
  • AML伴MF组3年OS率明显低于不伴MF组(20.5%对72.2%,χ²=4.032,P=0.045);MF-1和MF-2/3两组OS率、PFS率显著低于不伴MF组(P=0.001)。

关键数值与推荐

  • 103例中AML伴MF组46例(44.7%),其中MF-1 39例(84.8%),MF-2/3 7例(15.2%);AML不伴MF组57例(55.3%)。
  • 4例AML-M0患者均在AML伴MF组,AML不伴MF组AML-M2所占比例更高(P=0.014)。
  • Cox多因素分析显示MF尤其是MF-2/3是影响初诊AML患者OS和PFS的独立危险因素(P值分别为0.021和0.044)。

临床怎么用

  • 初诊AML应行骨髓活检评估MF,MF尤其MF≥2提示CR率及生存预后更差。
  • 伴MF的AML患者FLT3-ITD及NPM1突变率更高,CEBPA突变率更低,可辅助分子分型参考。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: This study aims to investigate the characteristics of gene mutation and clinical prognosis in de novo acute myeloid leukemia (AML) patients with myelofibrosis (MF) . Methods: From January 1, 2016, to February 1, 2020, 103 newly diagnosed AML patients in Henan Provincial People's Hospital who simultaneously underwent bone marrow biopsy examination were included. They were divided into the AML-MF group (MF grades 1-3) and the AML without MF group (MF grade 0) , and the clinical features, gene alterations, chemotherapy efficacy, and prognosis were compared between the two groups retrospectively. Results: ①MF was confirmed in 44.7% of AML patients (46/103) , of which 84.8% (39/46) were MF-1 and 15.2% (7/46) were MF-2/3, while MF was not confirmed in 55.3% (57/103) of AML patients. The median of WBC in the AML-MF group was significantly higher than in the AML without MF group [11.205 (0.69-191.82) ×10(9)/L vs 4.64 (0.18-95.10) ×10(9)/L, P=0.024]. More patients in the AML-MF group had nucleated erythrocytes in the peripheral blood (43.5% vs 24.6% , χ(2)=4.119, P=0.042) . All four AML-M(0) patients were in the AML-MF group, while AML without MF group had a higher proportion of AML-M(2) (P=0.014) . ②FLT3-ITD and NPM1 mutations were more frequent in the AML-MF group (P=0.021 and 0.039) , while CEBPA mutation was more frequent in the AML without MF group (P=0.029) . ③The CR rate in the AML-MF group was significantly lower than in the AML without MF group (69.7% vs 93.2% ) (χ(2) =7.412, P=0.006) . Multivariate analysis showed that MF, especially the grade of fibrosis, was an independent risk factor for CR in de novo AML. ④The 3-year OS of patients in the AML-MF group was significantly lower than in the AML without MF group (20.5% vs 72.2% , χ(2)=4.032, P=0.045) . Subgroup analysis showed that OS and PFS of AML-MF1 and AML-MF 2/3 groups were also significantly worse than those of the AML without MF group (P=0.001) and MF, especially MF ≥2, was an independent marker for inferior OS and PFS in de novo AML (P=0.021 and 0.044) . Conclusion: AML-MF has unique laboratory and clinical characteristics. MF is an independent risk factor for CR, OS, and PFS in AML. Evaluation of MF is very significant for therapy efficacy and prognosis judgment in de novo AML. 目的: 探讨初诊急性髓系白血病(AML)合并骨髓纤维化(MF)患者的基因突变、临床及预后特征。 方法: 2016年1月1日至2020年2月1日河南省人民医院收治的初诊并同时行骨髓活组织检查的103例AML患者纳入研究,根据WHO(2016)骨髓纤维化分级标准将患者分为AML伴MF组(MF-1~3)与AML不伴MF组(MF-0),并对两组患者的临床特征、基因突变、疗效和预后进行回顾性比较。 结果: ①103例患者中AML伴MF组46例(44.7%),其中MF-1 39例(84.8%),MF-2/3 7例(15.2%);AML不伴MF组57例(55.3%)。和AML不伴MF组相比,AML伴MF组中位WBC显著增高[11.205(0.69~191.82)×10(9)/L对4.64(0.18~95.10)×10(9)/L,P=0.024];外周血出现有核红细胞的比例明显增高(43.5%对24.6%,χ(2)=4.119,P=0.042);FAB分型:4例AML-M(0)患者均在AML伴MF组,而AML不伴MF组AML-M(2)所占比例更高(P=0.014)。②AML伴MF组患者FLT3-ITD及NPM1基因突变率更高(15.2%对1.8%,P=0.021;26.1%对10.5%,P=0.039),而CEBPA基因突变率明显低于AML不伴MF组(2.2%对17.5%,P=0.029)。③AML伴MF组完全缓解(CR)率显著低于AML不伴MF组(69.7%对93.2%,χ(2)=7.412,P=0.006)。多因素分析显示MF,尤其是纤维化程度是影响初诊AML患者CR的独立危险因素。④AML伴MF组3年总生存(OS)率明显低于AML不伴MF组(20.5%对72.2%,χ(2)=4.032,P=0.045);亚组分析显示MF-1和MF-2/3两组患者的OS率、无进展生存(PFS)率显著低于AML不伴MF组(P=0.001)。Cox多因素分析显示MF,尤其是MF-2/3是影响初诊AML患者OS和PFS的独立危险因素(P值分别为0.021和0.044)。 结论: AML合并MF患者具有较为独特的实验室及临床特征;MF是影响AML患者CR、OS和PFS的独立预后不良指标,MF的评估对初诊AML的疗效和预后判断具有重要意义。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Dong XY, Li YL, Wu CY, et al. [Analysis of clinical features, gene mutation, and prognostic characteristics in de novo acute myeloid leukemia patients with myelofibrosis]. Zhonghua Xue Ye Xue Za Zhi. 2020. PMID: 33113604. doi:10.3760/cma.j.issn.0253-2727.2020.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。